Zydus Lifesciences Ltd (ZYDUSLIFE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Mid Cap

Zydus Lifesciences Share Price

933.15 -2.05 -0.22%
as on 05-Dec'25 13:15

Zydus Lifesciences Ltd (ZYDUSLIFE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Mid Cap

DeciZen - make an informed investing decision on Zydus Lifesciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Zydus Lifesciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
19.13
Market Cap:
94,103 Cr.
52-wk low:
797.1
52-wk high:
1,059

Is Zydus Lifesciences Ltd an attractive stock to invest in?

1. Is Zydus Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Zydus Lifesciences Ltd is a good quality company.

2. Is Zydus Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Zydus Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Zydus Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Zydus Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Zydus Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zydus Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 28.6%16.5%18.6%15.9%10%14.4%15.3%13.6%24.9%26.1%-
Value Creation
Index
1.50.50.70.4-0.10.30.40.21.21.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 9,4279,37711,90513,16614,25314,40415,11017,23719,54723,24223,919
Sales YoY Gr.--0.5%27%10.6%8.3%1.1%4.9%14.1%13.4%18.9%-
Adj EPS 18.914.417.418.211.922.520.121.537.645.148.9
YoY Gr.--23.6%20.6%4.3%-34.5%89.5%-11%7.1%74.9%20.1%-
BVPS (₹) 55.76885.4101.4101.3126.9166173.1197.1238.1251.5
Adj Net
Profit
1,9361,4781,7821,8591,2172,3072,0542,1743,7804,5414,919
Cash Flow from Ops. 1,8941,3129191,2822,9323,2942,1052,6893,1966,777-
Debt/CF from Ops. 1.345.96.22.71.420.40.20.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.6%10.3%15.4%18.9%
Adj EPS 10.2%30.6%31%20.1%
BVPS17.5%18.6%12.8%20.8%
Share Price 9% 14.7% 31.2% -4.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
38.923.422.719.411.719.713.712.620.320.720
Op. Profit
Mgn %
24.720.323.922.719.623.62120.727.129.729.3
Net Profit
Mgn %
20.415.714.714.18.51614.212.819.319.920.6
Debt to
Equity
0.40.80.60.80.80.40.30.100.10.3
Working Cap
Days
1581781852132101031071029780129
Cash Conv.
Cycle
536380101103101820241662

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 20.00%

Sales growth is growing at healthy rate in last 3 years 15.43%

Net Profit is growing at healthy rate in last 3 years 31.03%

Sales growth is good in last 4 quarters at 15.05%

No data to display

Latest Financials - Zydus Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 48 48.9
TTM Sales (₹ Cr.) 13,347 23,919
BVPS (₹.) 215.1 251.5
Reserves (₹ Cr.) 21,541 25,201
P/BV 4.35 3.72
PE 19.50 19.13
From the Market
52 Week Low / High (₹) 797.05 / 1059.00
All Time Low / High (₹) 5.53 / 1323.90
Market Cap (₹ Cr.) 94,103
Equity (₹ Cr.) 100.6
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Zydus Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Zydus Lifesciences - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Zydus Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales9,4279,37711,90513,16614,25314,40415,11017,23719,54723,242
Operating Expenses 7,0977,4729,05810,18711,47311,01811,93513,66614,24816,348
Manufacturing Costs1,5531,1301,8922,1552,4832,5032,5722,9833,1243,804
Material Costs2,6733,0653,6574,1414,2434,0944,7575,3365,2605,345
Employee Cost 1,1191,4851,6451,9032,1702,0702,1782,4562,7893,290
Other Costs 1,7521,7921,8641,9882,5772,3522,4292,8903,0753,909
Operating Profit 2,3301,9042,8472,9782,7803,3853,1753,5725,2996,894
Operating Profit Margin (%) 24.7%20.3%23.9%22.6%19.5%23.5%21.0%20.7%27.1%29.7%
Other Income 11714713320911775391475369460
Interest 536311119634218612713081191
Depreciation 292373539599697670713723764916
Exceptional Items -3-00-10-364-205113-604-14-220
Profit Before Tax 2,0991,6152,3312,3821,4952,3992,8382,5904,8096,027
Tax 1771295645303201945125889781,412
Profit After Tax 1,9211,4861,7661,8521,1762,2062,3262,0023,8314,615
PAT Margin (%) 20.4%15.8%14.8%14.1%8.2%15.3%15.4%11.6%19.6%19.9%
Adjusted EPS (₹)18.914.517.318.111.520.843.819.438.445.0
Dividend Payout Ratio (%)17%22%20%19%30%17%6%31%8%24%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 5,6996,9608,74510,38610,37612,99217,00017,51619,83023,953
Share Capital 102102102102102102102101101101
Reserves 5,5976,8588,64210,28410,27312,89016,89717,41519,72923,853
Minority Interest1361561911293133519372054217322722405
Debt2,1074,9455,1137,1477,0413,6803,6761,0817693,170
Long Term Debt8962,4682,5553,9503,215610362000
Short Term Debt1,2112,4772,5583,1973,8273,0713,3141,0817693,170
Trade Payables1,3081,5481,8881,9232,0442,2062,1382,1252,1272,306
Others Liabilities 7827161,2041,7642,0381,9941,8321,6002,6403,024
Total Liabilities 10,03214,32517,14122,51322,83422,81026,70024,49427,63734,858

Fixed Assets

Gross Block5,7678,1039,34915,70216,78217,34517,65118,34419,92021,700
Accumulated Depreciation2,0172,3462,8673,5394,5515,2125,4626,8237,5518,566
Net Fixed Assets 3,7515,7576,48312,16412,23112,13312,18911,52112,36913,134
CWIP 9511,5431,5278377427837261,2012,4232,692
Investments 4164357466747658303,2881,5471,2216,408
Inventories1,3371,8042,3852,6882,7893,2363,7193,4133,4423,944
Trade Receivables1,7472,2783,2063,9513,6633,1273,3404,4175,2204,025
Cash Equivalents 6391,5441,3155499658881,1075731,1052,957
Others Assets 1,1929651,4791,6511,6801,8122,3311,8231,8571,699
Total Assets 10,03214,32517,14122,51322,83422,81026,70024,49427,63734,858

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 1,8941,3129191,2822,9323,2942,1052,6893,1966,777
PBT 2,0991,6122,3122,3821,4952,2855,2322,5834,8386,027
Adjustment 2503346245391,4741,163-2,1179345471,020
Changes in Working Capital 272-411-1384-972264191-336-236-9031532
Tax Paid -646-238-602-675-303-345-675-592-1,286-1,802
Cash Flow From Investing Activity -864-2,872-974-4,239-1,012-725-1,0001,535-1,475-8,372
Capex -957-2,935-1,035-1,046-889-847-1,055-992-883-1,661
Net Investments 16512-4,74629-39-2,8632,298-419-5,471
Others 7858501,554-1521612,918229-173-1,240
Cash Flow From Financing Activity -9352,316521,885-1,528-2,548-868-4,400-1,7792,014
Net Proceeds from Shares 000009870000
Net Proceeds from Borrowing -2371,4991011,808-786-2,568-674-841-830
Interest Paid -44-56-105-80-324-184-111-126-41-90
Dividend Paid -572-3270-358-715-2-372-267-621-303
Others -821,19956514296-781289-3,166-1,0342,406
Net Cash Flow 95756-3-1,07239122236-177-58419

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)38.6223.4722.519.3611.3218.8815.5111.620.5221.08
ROCE (%)28.616.5218.5515.8910.0214.3815.313.6424.926.06
Asset Turnover Ratio1.010.790.760.660.631.271.191.321.461.46
PAT to CFO Conversion(x)0.990.880.520.692.491.490.91.340.831.47
Working Capital Days
Receivable Days63778499974340424637
Inventory Days55606470703843383330
Payable Days164170171168171189167146148151

Zydus Lifesciences Ltd Stock News

Zydus Lifesciences Ltd FAQs

The current trading price of Zydus Lifesciences on 05-Dec-2025 13:15 is ₹933.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Zydus Lifesciences stood at ₹94,103.
The latest P/E ratio of Zydus Lifesciences as of 04-Dec-2025 is 19.50.
The latest P/B ratio of Zydus Lifesciences as of 04-Dec-2025 is 4.35.
The 52-week high of Zydus Lifesciences is ₹1,059 and the 52-week low is ₹797.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zydus Lifesciences is ₹13,347 ( Cr.) .

About Zydus Lifesciences Ltd

Zydus Lifesciences (Formerly known as Cadila Healthcare), a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.

The company provides pathbreaking and life-changing therapies that address unmet medical needs and enhance quality of life by supporting wellness and better health - whether through disease prevention, early detection, or effective management. With a focus on optimizing access and delivery, Zydus aims to revolutionize healthcare for the future. The company continues to unlock new possibilities in lifesciences through novel drug discoveries.

The company is fully committed to and continuously endeavors to achieve environment, health and safety excellence across all the units. The Company continues to invest substantial resources towards sustaining and continuously improving the standards of environment, occupational health and safety as it believes that its responsibility towards the society and the environment extends beyond those laid down by the regulatory authorities. The Company integrates sustainability deeply into its research and development (R&D) strategy, ensuring long-term impact and global health advancement. The Company’s R&D initiatives span across areas such as novel drug discovery, biosimilars, vaccines, specialty products and new dosage form development.

Business area of the company

The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. The company is committed to deliver high quality, affordable medicines to the patients by leveraging the best contemporary technology and process improvements.

Business verticals / products

  • India Formulations business: The Company’s formulations business in India has been a cornerstone of its overall growth strategy. 
  • Consumer Wellness: Zydus Wellness (ZWL), the Company’s subsidiary, spearheads the group’s operations in the consumer wellness space.
  • US Formulations business: The Company is one of the leading players in the US generics space, backed by a robust and diverse product portfolio that addresses a wide spectrum of therapeutic needs. The Company’s wholly owned subsidiary Zydus Pharmaceuticals USA Inc. spearheads the Company’s operations in the US.
  • International Markets Formulations business: International Markets formulations business will be the third pillar of growth for the Company beside the US and India geographies.

Awards

2008-09:

  • The Company received the 'Social and Corporate Governance Awards 2008' in the 'Best Social Responsibility Practice' category presented by the BSE, NASSCOM Foundation and Times Foundation jointly.

2009-10:

  • Received the 'IMAI OE Award for the Pioneering and Paradigm Shifting Applications of OE in Tablet Manufacturing' by the KAIZEN Institute.
  • Received the 'Best-In-Class Manufacturing Award (Pharma Sector)' by Stars of the Industry Awards.

2010-11:

  • Declared the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.

2011-12:

  • Zydus Research Centre, Ahmedabad has achieved the full AAALAC accreditation for the fourth year in a row. It has also received accreditation from College of American Pathologists (CAP) upon completion of the inspection process. This accreditation was received in the first inspection itself.

2012-13:

  • The Gujarat Ecology Commission selected the Company for good ‘Environment-friendly Practices in Gujarat’. Zydus Research Centre won the Safety Award for the third consecutive year from Gujarat Safety Council.

2013-14:

  • Moraiya formulations facility was awarded the 'Gold Award - Pharma Sector, Mega Large Business' by The Economic Times and Frost & Sullivan for achieving operational excellence.

2014-15:

  • The Moraiya formulations facility was awarded the 'Green Manufacturing Award - Gold Category' by International Research Institute for Manufacturing.
  • The Baddi formulations facility was awarded 'Gold Certificate Merit' in IMEA - India Manufacturing Excellence Awards 2014 by The Economic Times in partnership with Frost & Sullivan.

2015-16:

  • It was awarded the Overall India Pharma Excellence Award and the India Pharma Innovation of the Year Award from the Department of Pharmaceuticals, Government of India.

2016-17:

  • Topical formulations facility received the ‘Silver Certificate of Merit’ from Frost & Sullivan at India Manufacturing Excellence Awards 2016.

2017-18:

  • The manufacturing sites at Moraiya, Baddi and Sikkim received the Silver medal at the National Award for Manufacturing Competitiveness (NAMC) by IRIM global.
  • API manufacturing facility at Ankleshwar Ank Unit I bagged a Silver at the Greentech Safety Award 2017 in recognition of its safety systems from the Greentech Foundation, Environment.

2018-19:

  • Moraiya formulations manufacturing facility received the Gold Award in the category of Pharma Sector, Large Business at the India Manufacturing Excellence Awards, 2018.

2019-20:

  • Cadila Healthcare Limited received CSIR Diamond Jubilee Technology Award for Discovery & Development of Saroglitazar in June 2019.
2020-21

  • Cadila Healthcare received the ‘Golden Peacock Quality Award’ for the year 2020.
  • Cadila Healthcare (API Division) Dabhasa unit also won the “Golden Peacock Environment Management Award” for the year 2020. 
2021-22

  • Pharma Company of The Year Award by ET Healthworld India Pharmaworld Awards 2022.
  • 7th India Pharma and India Medical Device award by the Government of India, Department of Pharmaceuticals in the India Pharma CSR of the year category.
  • Received gold award in the 8th National CSR Summit and CSR Times Award in the healthcare category.
2022-23

  • Received three awards - 1 Gold and 2 Silver Awards for Best Design for Corporate Identity, Brand Logo and Re-Branding. from India Design Excellence Awards.
  • Zydus Lifesciences was featured among Top 40 India’s Best Workplaces in Health & Wellness for 2022.
  • Confederation of Indian Industry (CII) Silver Award Winner for Zero Raw Material Wastage- Yield Improvement in Tab-X.
2024-25

  • Zydus has been recognised by the Asia Book of Records for the highest number of doctors participating in a flu vaccination drive within a single week.
  • Zydus received Mahatma Award India 2024 for ESG Excellence.
  • Zydus Wellness was certified by the Great Place to Work for the 3rd time.
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×